NHRI Enters Technology Transfer Agreement of DBPR211 with Applied Biopharma LLC, wholly owned by Agentix Corp. (AGTX) in the US

National Health Research Institutes (NHRI) and Applied BioPharma LLC have signed the technology transfer agreement on May, 2021. Applied Biopharma is a wholly owned subsidiary by Agentix Corp. (OTC: AGTX) and has granted the exclusive rights of the antidiabetic drug, DBPR211, with global patents.

About DBPR211

Developed by IBPR, DBPR211 is a potent antagonist selectively acting on the peripheral cannabinoid receptor type 1 (CB1) receptors which had received IND approvals from the US FDA and Taiwan FDA in 2016 and 2017, respectively.

About Agentix

AGENTIX is a vertically integrated company focused on the development and commercialization of both established cannabinoid pharmaceuticals, leveraging molecules already approved for pharmaceutical applications with lower clinical risks and shorter timelines to market, as well as novel, science-driven, synthetic cannabinoid biopharmaceuticals that target the endocannabinoid system to treat a wide-range of diseases across multiple therapeutic areas with greater market exclusivity. For more information, please visit www.agentixcorp.com

About IBPR of the NHRI

Institute of Biotechnology and Pharmaceutical Research of the NHRI is a mission-driven drug discovery and development engine with vertical and horizontal coordination and integration. For more information, visit https://ibpr.nhri.org.tw/en/ .

Link 2:https://finance.yahoo.com/news/agentix-corporation-national-health-research-120000896.html

Link 3:https://cannin.com/agentix-corporation-and-the-national-health-research-institutions-announce-worldwide-exclusive-license-agreements/